Dennis Hsu

Dennis Hsu

Auto-generated profile, based on publicly available information

Dennis Hsu

UPMC Hillman Cancer Center, Division of Malignant Hematology and Oncology, University of Pittsburgh Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ACAKSHIT CHITKARA
AKSHIT CHITKARA
MBMuhammad Bakhtiar
Muhammad Bakhtiar
ISIbrahim Sahin
Ibrahim Sahin
DHDennis Hsu
Dennis Hsu
JZJanie Zhang
Janie Zhang
ASAnwaar Saeed
Anwaar Saeed
Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2-positive agents like trastuzumab alone, promising results have been observed when combined with other synergistically acting tyrosine kinase inhibitors (TKIs). Our meta-analysis was conducted following the Cochrane Handbook and written following the PRISMA guidelines. The protocol was registered on PROSPERO with the registration number CRD42022338935. After a comprehensive search for relevant articles, 14 CTs were identified and uploaded to Rayyan, and six trials were ultimately selected for inclusion. The meta-analysis revealed that a median of three prior lines of therapy was used before enrolling in the six trials comprising 238 patients with HER2-positive metastatic colorectal cancer (mCRC). The pooled objective response rate (ORR) and disease control rate (DCR) were 31.33% (95% confidence interval [CI] 24.27–38.39) and 74.37% (95% CI 64.57–84.17), respectively. The pooled weighted progression-free survival (PFS) was 6.2 months. The pooled ORR and DCR meta-analysis indicate a significant response to HER2-targeted therapy in this patient in HER2-positive mCRC. Additionally, a pooled PFS of 6.2 months suggests that HER2-targeted treatment regimens are associated with a meaningful improvement in survival outcomes in this population.

14 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
Parham HabibzadehParham Habibzadeh
Parham Habibzadeh
JSJohn Sorkin
John Sorkin
DHDennis Hsu
Dennis Hsu
Introduction: Cancer remains a leading cause of global morbidity and mortality, underscoring the need for accessible biomarkers for early detection and risk stratification. The red blood cell distribution width‐to‐albumin ratio (RAR) integrates inflammation and nutritional markers often dysregulated in cancer. We evaluated RAR's association with a recent diagnosis (≤ 1 year) of breast, colorectal, lung, and prostate cancer in a representative US population. Methods: Using National Health and Nutrition Examination Survey data (2005–2018), we conducted a cross‐sectional analysis of adults with recent diagnoses (≤ 1 year) of a single primary cancer. Propensity score matching balanced cases and cancer‐free comparisons by age, sex, and race. Weighted logistic regression assessed associations between a 1‐unit RAR (%dL/g) increase and cancer presence, reporting adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Results: The analysis included 48 breast, 31 colorectal, 19 lung, and 77 prostate cancer cases, along with their matched comparisons. A 1% dL/g increase in RAR was significantly associated with higher odds of breast (adjusted OR 1.62, 95% CI 1.17–2.24), colorectal (adjusted OR 1.56, 95% CI 1.01–2.40), and lung cancer (adjusted OR 1.95, 95% CI 1.44–2.66). No significant association was observed for prostate cancer (adjusted OR 1.05, 95% CI 0.69–1.59). Conclusion: RAR is significantly associated with a recent diagnosis of breast, colorectal, and lung cancers, but not prostate cancer. These findings suggest RAR may reflect cancer‐associated systemic alterations, warranting further prospective study to validate its clinical applicability.